DDDigamber Dabhade

Digamber Dabhade

*This is an algorithmically generated author record based on publicly available information.

Digamber Dabhade has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study

    by Sanjay Pujari, Sunil Gaikwad, Suhrud Panchawagh, Abhishek Chitalikar, Kedar Joshi, Chaitrangi Rohekar, Diagamber Dabhade, Vivek Bele

    We assessed the effectiveness and safety of switching to generic dolutegravir/lamivudine (DTG/3TC) among People living with Human Immunodeficiency Virus (PWH) in Western India. In this single-center, retrospective observational study, PWH, who switched to DTG/3TC, were followed for virologic, immunologic, and clinical effectiveness, and safety, including weight changes, hyperglycemia, and dyslipidemia. Multivariate linear mixed-effects models were used to predict average change in weight adjusted for age, sex, duration of previous antiretroviral (ARV) regimens, and baseline weight. From May 2017 to July 2022, out of 434 PWH switched to DTG/3TC, 304 with at least 1 follow-up visit were included. Median [interquartile range (IQR)] age was 54 (IQR 49–61) years and 70.1% were male. Prevalence of baseline comorbidities was 57.9% (hypertension—41.5%, chronic kidney disease—40.9%, and diabetes mellitus—18.8%). Reasons for switch were affordability (47.4%), desire for simplification (41.8%), ARV toxicities (19.1%), and concern about potential toxicities (10.2%). Median (IQR) duration of follow-up on DTG/3TC was 40 (IQR 31–49) weeks. No virologic failure was observed. Rates of virologic suppression [viral load (VL) ≤20 copies/mL or target not detected (TND)] at 12, 24, 48, 72, 96 and 120 weeks were 95.2%, 95.9%, 90%, 100%, 81.3%, and 88.4%, respectively. Only 9 (3%) PWH permanently discontinued DTG/3TC. Predicted adjusted mean weight gain of +3.3 kg was observed at 96 weeks. Switching from tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC)/non-nucleoside reverse transcriptase inhibitor (NNRTI) and duration on DTG/3TC were significantly associated with weight gain. Apart from trend in worsening hyperglycemia (nine PWH with new onset diabetes), no clinically significant change in lipids and estimated glomerular filtration rate (eGFR) was documented. Switching to DTG/3TC is an effective and safe option among virologically suppressed PWH with high comorbidity burden in India. In view of the several advantages of DTG/3TC, it may be considered for potential scale-up in the right population, both in private and public health care settings in India.


  • Short Communication: Coronavirus Disease 19 Among People Living with HIV in Western India: An Observational Cohort Study

    by Sanjay Pujari, Sunil Gaikwad, Abhishek Chitalikar, Digamber Dabhade, Kedar Joshi, Vivek Bele

    A retrospective cohort study was conducted to assess clinical characteristics and outcomes of COVID-19 amongst People Living with HIV (PLHIV) in Western India. Out of 86 PLHIV with COVID-19 illness, 19.7% had severe/critical illness and 6 (6.9%) individuals died. Median (IQR) age was 51 (47-56) years and 77.6% were male. Eighty-five PLHIV were on antiretroviral treatment with 98% having a Viral load < 200 copies/ml. Hypertension (38.3%) and Diabetes mellitus (17.4%) were commonest co-morbidities. Fifty-eight percent PLHIV were hospitalized while 6.9% individuals needed Intensive care. Presence of medical co-morbidity was significantly associated with severe/critical COVID-19, while Hypertension was significantly associated with mortality. Recovery from COVID-19 was documented in 93% PLHIV. In conclusion, PLHIV in Western India have similar COVID-19 clinical outcomes as compared to that reported historically amongst general population. Presence of medical co-morbidities rather than HIV related disease characteristics are associated with severe COVID-19 illness.


  • Open Access

    Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom

    by Sanjay N Pujari, Colette Smith, Abhimanyu Makane, Mike Youle, Margaret Johnson, Vivek Bele, Kedar Joshi, Digamber Dabhade, Sanjay Bhagani

    Data on the renal safety of Tenofovir (TDF) in Low and Middle Income Countries (LMICs) is scarce. We compared development of various forms of renal impairment with use of TDF-containing antiretroviral therapy (ART) between a cohort from the Institute of Infectious Diseases (IID) Pune, Western India and the Royal Free Hospital (RFH) London, UK.